FDA Panel Says Endo Painkiller Risks Exceed Benefits
A U.S. Food and Drug Administration advisory committee tasked with reviewing the risks of Endo Pharmaceutical's opioid painkiller Opana ER determined that they outweigh its benefits on Tuesday, following a two-day...To view the full article, register now.
Already a subscriber? Click here to view full article